UTAH MEDICAL PRODUCTS INC(UTMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,701 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
UTMD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for UTAH MEDICAL PRODUCTS INC (UTMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UTMD at 48.8/100 on a 32-signal composite quality model, placing it at rank #1,701 of 2,962 stocks — the bottom half of the AI-ranked universe. UTMD scores in the top quartile across free cash flow (85.4), profitability (85.0), balance sheet strength (82.2). Areas of concern include revenue scale (6.5) and revenue growth (6.8), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), UTAH MEDICAL PRODUCTS INC reports quarterly revenue of $8.5M, net income of $2.7M, an operating margin of 31.1%. Top institutional holders of UTMD by reported 13-F value include BRANDES INVESTMENT PARTNERS, BlackRock, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. UTMD trades on the Nasdaq exchange and files with the SEC under CIK 706698. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UTMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UTAH MEDICAL PRODUCTS INC directly from SEC EDGAR. UTAH MEDICAL PRODUCTS INC's 13F Pro composite quality score has ranged between 47 and 65 since 2021, currently 48.8 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$8.5M
Net Income
Q2 2026
$2.7M
Free Cash Flow
Q2 2026
$1.2M
Operating Margin
Q2 2026
31.1%
ROIC
Q2 2026
8.7%
D/E Ratio
Q2 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-5.8% YoYOperating Income
-16.1% YoYEPS (Diluted)
-12.1% YoYTotal Assets
+0.0% YoYTotal Debt
-20.2% YoYOp. Cash Flow
-0.9% YoYFree Cash Flow
-1.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $38.5M -5.8% | $40.9M -18.6% | $50.2M -3.9% | $52.3M +6.6% | $49.1M +16.3% | $42.2M |
| Operating Income | $11.4M -16.1% | $13.6M -19.0% | $16.8M -15.2% | $19.8M +4.8% | $18.9M +37.7% | $13.7M |
| EPS (Diluted) | $3.48 -12.1% | $3.96 -13.3% | $4.57 +1.1% | $4.52 +11.9% | $4.04 +37.4% | $2.94 |
| Total Assets | $122.5M +0.0% | $122.5M -9.5% | $135.5M +9.4% | $123.9M +7.1% | $115.6M +3.5% | $111.7M |
| Total Debt | $225.0K -20.2% | $282.0K -4.4% | $295.0K | $0.00 | $0.00 | $0.00 |
| Operating Cash Flow | $14.7M -0.9% | $14.8M -33.4% | $22.3M +5.4% | $21.1M -0.3% | $21.2M +5.3% | $20.1M |
| Free Cash Flow | $14.3M -1.9% | $14.6M -32.5% | $21.6M +6.4% | $20.3M -1.5% | $20.7M +7.1% | $19.3M |
Get alerted when UTMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for UTAH MEDICAL PRODUCTS INC including:
Top Institutional Holders of UTMD
BRANDES INVESTMENT PARTNERS, LP
$32.8M475,158 shBlackRock, Inc.
$14.1M203,690 shDIMENSIONAL FUND ADVISORS LP
$13.7M198,817 shRENAISSANCE TECHNOLOGIES LLC
$12.1M175,814 shVANGUARD CAPITAL MANAGEMENT LLC
$9.3M134,535 shGEODE CAPITAL MANAGEMENT, LLC
$7.5M108,048 shMinerva Advisors LLC
$6.5M93,615 shHOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$5.9M85,231 shRICE HALL JAMES & ASSOCIATES, LLC
$4.9M71,363 shMORGAN STANLEY
$4.8M69,671 sh
| Fund | Value | Shares |
|---|---|---|
| BRANDES INVESTMENT PARTNERS, LP | $32.8M | 475,158 |
| BlackRock, Inc. | $14.1M | 203,690 |
| DIMENSIONAL FUND ADVISORS LP | $13.7M | 198,817 |
| RENAISSANCE TECHNOLOGIES LLC | $12.1M | 175,814 |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.3M | 134,535 |
| GEODE CAPITAL MANAGEMENT, LLC | $7.5M | 108,048 |
| Minerva Advisors LLC | $6.5M | 93,615 |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $5.9M | 85,231 |
| RICE HALL JAMES & ASSOCIATES, LLC | $4.9M | 71,363 |
| MORGAN STANLEY | $4.8M | 69,671 |
Companies Similar to UTMD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Pediatrix Medical Group, Inc.
Prestige Consumer Healthcare Inc.
NRC HEALTH
SBC Medical Group Holdings Inc
InMode Ltd.
Amphastar Pharmaceuticals, Inc.
PUMA BIOTECHNOLOGY, INC.
Bioventus Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put UTMD on your watchlist
Track score changes the day UTAH MEDICAL PRODUCTS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is UTMD a good stock to buy?
13F Pro's AI-powered analysis of UTAH MEDICAL PRODUCTS INC (UTMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UTMD are available on the UTMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. UTMD is classified as a small company.
Which hedge funds own UTMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UTMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of UTAH MEDICAL PRODUCTS INC's investment landscape.